June 2022
Volume 63, Issue 7
Open Access
ARVO Annual Meeting Abstract  |   June 2022
Pulmonary function in school-age children following intravitreal injection of bevacizumab for retinopathy of prematurity
Author Affiliations & Notes
  • Wei-Chi Wu
    Ophthalmology, Chang Gung Medical Foundation, Taoyuan, Taiwan
  • Footnotes
    Commercial Relationships   Wei-Chi Wu None
  • Footnotes
    Support  Supported in part by the Chang Gung Memorial Hospital, Taoyuan, Taiwan (grant no.: CMRPG3K0421, CMRPG3I0071~3 and CMRPG3J0121~3); and the Ministry of Science and Technology, Taiwan (grant no.: MOST 109-2314-B-182A-019-MY3 and MOST 109-2314-B-182-042-MY3).
Investigative Ophthalmology & Visual Science June 2022, Vol.63, 4203 – F0263. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Wei-Chi Wu; Pulmonary function in school-age children following intravitreal injection of bevacizumab for retinopathy of prematurity. Invest. Ophthalmol. Vis. Sci. 2022;63(7):4203 – F0263.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate pulmonary function in school-age children who have received intravitreal bevacizumab (IVB) for retinopathy of prematurity (ROP).

Methods : In this retrospective, cross-sectional case-control study of 118 school-aged children were separated into three groups: full-term control children (group 1), preterm children who had not received IVB treatment (group 2) and preterm children with ROP who had received IVB treatment (group 3). Pulmonary function, measured by spirometry and impulse oscillometry, was assessed at approximately 7 years of age and compared among the three groups.

Results : One hundred and eighteen children (65 boys and 53 girls; mean age, 6.67±0.52 years) were included in this study. Pulmonary function was significantly better in group 1 than in groups 2 and 3 (all p < 0.05 in forced vital capacity (FVC), forced expiratory volume in 1 second (FEV1), forced expiratory flow between 25% and 75% of FVC (FEF25-75), resistance of the respiratory system at 5 Hz (R5) and difference between R5 and R20 (R5-R20)). There were no statistically significant differences between group 2 and group 3 in FVC, FEV1, ratio of FEV1 to FVC (FEV1/FVC), FEF25-75, resistance of the respiratory system at 20 Hz (R20), reactance of the respiratory system at 5 Hz (X5) or R5-R20 after adjusting for important perinatal factors.

Conclusions : By school age, preterm infants with a history of receiving IVB for ROP had comparable pulmonary function to their preterm peers who had not received IVB treatment.

This abstract was presented at the 2022 ARVO Annual Meeting, held in Denver, CO, May 1-4, 2022, and virtually.

 

Figure 1. Flowchart showing the inclusion and exclusion of patients during the study period. IVB = intravitreal injection of bevacizumab; ROP = retinopathy of prematurity
*Full-term children were matched to groups 2 and 3 by age at pulmonary function testing.
One patient received IVB in the right eye and laser treatment in the left eye.
One patient received IVB in the right eye and combined IVB and laser treatment in the left eye.

Figure 1. Flowchart showing the inclusion and exclusion of patients during the study period. IVB = intravitreal injection of bevacizumab; ROP = retinopathy of prematurity
*Full-term children were matched to groups 2 and 3 by age at pulmonary function testing.
One patient received IVB in the right eye and laser treatment in the left eye.
One patient received IVB in the right eye and combined IVB and laser treatment in the left eye.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×